Evidence map›Paper›PMID 39261766›Full record

ArticleBMC gastroenterology2024

Comparative real-world outcomes between ustekinumab, infliximab, and adalimumab in bio-naïve and bio-experienced Crohn's disease patients: a retrospective multicenter study.

Ji Eun Na, Yong Eun Park, Jongha Park, Tae-Oh Kim, Jong Hoon Lee, Su Bum Park, Soyoung Kim, Seung Bum Lee, Busan Ulsan Gyeongnam Intestinal Study Group Society (BIGS)

Abstract readMulticenter StudyComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC gastroenterology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Ji Eun NaDepartment of Internal Medicine, Inje University Haeundae Paik Hospital, Busan, South Korea.
Yong Eun ParkDepartment of Internal Medicine, Inje University Haeundae Paik Hospital, Busan, South Korea.
Jongha ParkDepartment of Internal Medicine, Inje University Haeundae Paik Hospital, Busan, South Korea.
Tae-Oh KimDepartment of Internal Medicine, Inje University Haeundae Paik Hospital, Busan, South Korea. kto0440@paik.ac.kr.
Jong Hoon LeeDepartment of Internal Medicine, Dong-A University College of Medicine, Busan, South Korea.
Su Bum ParkDepartment of Internal Medicine, Pusan National University School of Medicine and Research Institute for Convergence of Biomedical Science and Technology, Pusan National University Yangsan Hospital, Yangsan, South Korea.
Soyoung KimDepartment of Gastroenterology, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, South Korea.
Seung Bum LeeDepartment of Gastroenterology, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, South Korea.
Busan Ulsan Gyeongnam Intestinal Study Group Society (BIGS)

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundNumerous studies have compared the efficacy of ustekinumab (UST) and anti-TNF agents [infliximab (IFX) or adalimumab(ADA)] in moderate to severe Crohn's disease (CD) patients. This study aims to compare the efficacy of UST, IFX, and ADA while differentiating between bio-naïve and bio-experienced patients, which is an underexplored aspect, particularly in Asia.

methodsWe conducted a retrospective multi-center study from 2012 to 2023, categorizing patients into bio-naïve and bio-experienced groups. We evaluated clinical remission rates after induction therapy and clinical outcomes, including CD-related hospitalization, intestinal resection, and drug discontinuation during maintenance therapy.

resultsAmong the 214 bio-naïve CD patients, 60 received UST, 108 received IFX, and 46 received ADA. After 1:1 propensity score matching between UST and anti-TNF agents groups, 59 patients were analyzed in each group (45 in the IFX group and 14 in the ADA group). We found no significant differences in clinical remission rates (P = 0.071), CD-related hospitalization (P = 0.800), intestinal resection (P = 0.390), or drug discontinuation (P = 0.052) between the UST, IFX, and ADA groups in bio-naïve CD patients. In bio-experienced CD patients, with 35 in the UST group and 13 in the anti-TNF agents group, the UST group showed a lower risk of drug discontinuation (P = 0.004) than the anti-TNF agents group.

conclusionsThis study suggests that UST, IFX, and ADA are equally effective in bio-naïve CD patients, while in bio-experienced patients, mostly with previous exposure to anti-TNF agents, UST may offer superior drug durability.

Indexed as

AdalimumabCrohn DiseaseInfliximabRemission InductionUstekinumabAdultFemaleGastrointestinal AgentsHospitalizationHumansMaleMiddle AgedRetrospective StudiesTreatment OutcomeTumor Necrosis Factor InhibitorsYoung AdultAdalimumabGastrointestinal AgentsInfliximabTumor Necrosis Factor InhibitorsUstekinumabBio-naïve and bio-experienced patientsEfficacy and prognosisModerate to severe Crohn’s diseaseUstekinumab and anti-tumor necrosis factor agents

Identifiers

PMID39261766
PMCPMC11389048

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.